As one of the world’s best-selling cancer drugs, bevacizumab is quickly becoming a promising option for mesothelioma patients. Also known as the brand name Avastin, bevacizumab inhibits the formation of new blood vessels in tumors, effectively slowing the growth of cancer cells.
In early clinical trials, bevacizumab (Avastin) helped some mesothelioma patients live longer when combined with chemotherapy drugs cisplatin and pemetrexed (Alimta). Bevacizumab improved survival time by 2.7 months in a 2016 phase III clinical trial in France. Patients taking a combination of the three drugs survived an average of 18.8 months, compared to 16.1 months for patients only receiving cisplatin and pemetrexed.
However, bevacizumab’s rare but serious side effects have some researchers questioning its safety. The phase III clinical trial showed that although the side effects were significantly higher for patients taking bevacizumab, they were deemed mostly manageable.
Doctors may inject the drug or give it through an intravenous drip, a process that can take a few hours. Patients generally need the drug once every three days.
Bevacizumab is sometimes classified as a chemotherapy drug, but it does not fight cancer in the usual way. Whereas typical chemotherapy attacks rapidly dividing cancer cells, this drug ensures that tumors don’t receive necessities like oxygen and nutrients. It does this by inhibiting angiogenesis, which is the growth of blood vessels within the tumor. If angiogenesis occurs, mesothelioma cells have a support system within the body and can divide and spread more easily. But without angiogenesis, cancer cells are starved of vital nutrients and slowly die. When bevacizumab prevents angiogenesis, it stops mesothelioma from spreading and kills cancer cells that are already present.
15 mg/kg every three weeks
Quadramet, deferiphrone, pantiumumab, sunitinib, thalidomide
Gastrointestinal perforation or fistula, arterial thromboembolic events, hypertension, proteinuria, ovarian failure, infusion reactions, posterior reversible encephalopathy syndrome
In some cancers, including mesothelioma, it is commonly used in combination with other chemotherapy drugs such as gemcitabine. This way, bevacizumab works to stop angiogenesis while other drugs focus on attacking the tumor itself. However, research shows that some combinations with bevacizumab can lead to deadly side effects.
Bevacizumab commonly causes minor side effects such as dizziness, dry mouth, fatigue, heartburn and loss of appetite. In rare cases, it may cause severe side effects such as blood clots in the lungs, hemorrhaging, holes in the stomach and low white blood cell count. These potentially deadly complications are most common when it is used in conjunction with a chemotherapy drug.
A study of clinical trial results revealed that patients treated with bevacizumab and chemotherapy are 1.5 times more likely to die because of treatment complications than patients treated with chemotherapy alone. Some argue that the death rate is still low at 2.5 percent and that the potential benefits of the drug are worth it. When used against deadly cancers like mesothelioma, the elevated death rate may be a small risk for a drug that may extend life span in most patients.
A 2008 study tested the effects of bevacizumab with chemotherapy in 24 mesothelioma patients who previously underwent other treatments with no positive results. The combination was successful in slowing disease progression in half of patients. Overall, patients lived a median of 5.8 months after being treated with the drug. Researchers reported that it was well-tolerated and warranted further study.
In a case study the following year, a mesothelioma patient underwent treatment with bevacizumab and gemcitabine after other treatments had failed to shrink his tumor or control his symptoms. The combination helped prevent fluid buildup and pain, leading to a better quality of life. This finding suggests that bevacizumab may aid in palliative, symptom-reducing care in addition to potentially curative, life-extending treatment.
Karen Selby joined Asbestos.com in 2009. She is a registered nurse with a background in oncology and thoracic surgery and was the director of a tissue bank before becoming a Patient Advocate at The Mesothelioma Center. Karen has assisted surgeons with thoracic surgeries such as lung resections, lung transplants, pneumonectomies, pleurectomies and wedge resections. She is also a member of the Academy of Oncology Nurse & Patient Navigators.
View our resources for patients and familiesGet Help Today